Heparin affin regulatory peptide (HARP) is an heparinbinding molecule involved in the regulation of cell proliferation and differentiation. Here, we report that HARP inhibited the biological activity induced by the 165-amino-acid form of vascular endothelial growth factor (VEGF 165 ) on human umbilical vein endothelial cells. Endothelial-cell proliferation induced by VEGF 165 showed about 50% inhibition in the presence of HARP in a concentration of 3 nM. In similar range of concentrations, HARP blocked tube formation induced by VEGF 165 in three-dimensional angiogenesis assay. In vivo studies showed that HARP inhibited the VEGF 165 -induced Matrigelt infiltration of endothelial cells. We then investigated the mechanisms of this inhibition and shown that HARP inhibited the binding of I-VEGF 165 to fms-like tyrosine kinase I receptor was unaffected. A competitive affinity-binding assay demonstrated that HARP interacted directly with VEGF 165 with a dissociation coefficient of 1.38 nM. Binding assay using deletion mutants of HARP revealed that the thrombospondin type-1 repeats domains were involved in this interaction. These data demonstrate for the first time that the angiogenic factor HARP can also negatively regulates the angiogenic activity of VEGF 165 .
Heparin affin regulatory peptide (HARP) is an heparinbinding molecule involved in the regulation of cell proliferation and differentiation. Here, we report that HARP inhibited the biological activity induced by the 165-amino-acid form of vascular endothelial growth factor (VEGF 165 ) on human umbilical vein endothelial cells. Endothelial-cell proliferation induced by VEGF 165 showed about 50% inhibition in the presence of HARP in a concentration of 3 nM. In similar range of concentrations, HARP blocked tube formation induced by VEGF 165 in three-dimensional angiogenesis assay. In vivo studies showed that HARP inhibited the VEGF 165 -induced Matrigelt infiltration of endothelial cells. We then investigated the mechanisms of this inhibition and shown that HARP inhibited the binding of Angiogenesis is an important process, which plays a central role in various physiological and pathophysiological processes. The generation of new capillaries is a multistep process that includes degradation of the basement membrane of pre-existing vessels, migration and proliferation of endothelial cells, and stabilization of new vascular tubes (Folkman, 1971; Folkman and Shing, 1992) . There is now convincing evidence that the control of angiogenesis involves a balance between angiogenic and angiostatic molecules (Cross and Claesson-Welsh, 2001) . A variety of growth factors capable of inducing angiogenesis have been identified, with the most important and extensively studied being vascular endothelial growth factor (VEGF) and fibroblast growth factors. Available data identify VEGF as a critical regulator of both normal and abnormal angiogenesis (Ferrara and Henzel, 1989; Plouet et al., 1989) . For example, VEGF is overexpressed in tumors, where it stimulates angiogenesis and promotes tumor growth (Folkman, 1995) . This finding sparked off efforts to design drugs capable of interfering with VEGF signaling, thereby blocking tumor angiogenesis (Tomanek and Schatteman, 2000) . Over the last decade, several studies have focused on the development and characterization of molecules with angiostatic properties (Cao, 2001) . Accordingly, various endogenous inhibitors of angiogenesis have been characterized, including angiostatin (O'Reilly et al., 1994) , endostatin (O'Reilly et al., 1997) , platelet factor-4 (Maione et al., 1991) , and thrombospondin-1 (TSP-1) (Good et al., 1990) .
In the last decade, we and others have shown that heparin affin regulatory peptide (HARP) (Rauvala, 1989) , a neurite outgrowth promoting molecule, induces the proliferation of various cell types including fibroblasts, epithelial cells, and endothelial cells (Courty et al., 1991; Fang et al., 1992; Papadimitriou et al., 2000) . Compelling evidence that HARP contributes to the regulation of angiogenesis has been reported (Laaroubi et al., 1994; Choudhuri et al., 1997; Delbe et al., 1999) . Moreover, both HARP protein and its mRNA have been identified in blood vessels and capillaries in mammary gland (Ledoux et al., 1997) , prostate (Vacherot et al., 1999) , and uterus (Milhiet et al., 1998) . In a previous report, we studied the biological properties of HARP in various angiogenesis assays and observed a slight inhibiting effect of HARP on tube formation by human umbilical vein endothelial cells (HUVEC) (Papadimitriou et al., 2001) . The data reported in this article provide evidence that HARP can inhibit in vitro as well as in vivo VEGF activity and shed light on the mechanisms involved.
Materials and methods

Materials
Human recombinant VEGF 165 was expressed in sf9 insect cells and purified by cation exchange and heparin-affinity chromatography, as previously reported (Plouet et al., 1997) . Human recombinant HARP of bacterial origin was produced and purified as previously described (Seddon et al., 1994) . Sterile plastic ware was from Techno Plastic Products (Zollstrasse, Switzerland).
125
I-Na was provided by ICN (Orsay, France). Iodobeads s and disuccinimidyl suberate (DSS) crosslinking reagent were purchased from Perbio Science France (Bezons, France). EBM-2 BulletKit s medium was from Biowhittaker (Emerainville, France), and the other culture media as well as fetal calf serum (FCS) were supplied by Invitrogen Life Technologies (Cergy Pontoise, France). Fc-coupled soluble VEGF receptors were purchased from R&D (Oxon, UK).
Cell culture and proliferation assay
HUVEC were provided by Clonetics (Biowhittaker, Emerainville, France) and routinely cultured in EBM-2 BulletKit s supplemented medium with 2% FBS. Cultures were grown at 371C in a humidified atmosphere of 95% air and 5% CO 2 . All experiments were carried out between passages 2 and 5. For cell proliferation assays, HUVEC were seeded into six-well plates (20 000 cells/well) in EBM-2 supplemented with 2% FBS in the presence or absence of VEGF 165 (10 ng/ml) with or without HARP. The medium was renewed on day 3 and the cells were counted on day 5 using a Coultronics Coulter counter (Beckman Coulter, Roissy, France).
In vitro tube formation assay HUVEC were plated on a basement membrane matrix preparation depleted of growth factors (Matrigelt, Beckton Dickinson, Le pont de Claix, France). Matrigelt was used to coat 24-well plates (250 ml per plate) according to the manufacturer's instructions and was allowed to solidify at 371C for 60 min. The solidified Matrigelt was then overlaid with 500 ml EBM-2 containing 8 Â 10 4 HUVEC supplemented with 2% FCS with or without growth factors. After incubation at 371C for 4-6 h, tube network formation was quantified as previously described (Pipili-Synetos et al., 1998) .
In vivo mouse Matrigel t plug assay
Batches of four Swiss mice (Janvier, Le Genest St Isle, France) were subcutaneously injected with 0.2 ml Matrigelt alone or containing proteins according to our previously described procedure (Bernard-Pierrot et al., 2002) . The injected Matrigelt rapidly formed a single solid gel plug. Mice were killed after 6 days, and the Matrigelt plugs were excised and frozen in liquid nitrogen. Sample sections of 10 mm thick were made using a cryostat (Leica) and extemporaneously stained with Gomori-Trichrome for microscopic observation. Endothelial cell invasion and vessel ingrowth were quantified by computer image analysis using the NIH image analysing software. (1-2 ng/ml) in the presence of various competitors, as indicated in the legend of the figures. At the end of the incubation period, the wells were washed three times with ice-cold binding buffer, and the bound 125 I-VEGF 165 was solubilized in 0.5 ml of 0.2 M NaOH and counted in a gamma counter (LKB Wallac Minigamma 1275). All the experiments were carried out in duplicate and repeated at least three times. Chemical crosslinking experiments were performed as previously described (Plouet and Moukadiri, 1990) , with minor modifications. Briefly, subconfluent HUVEC cultures were washed twice with cold binding buffer and incubated on an oscillator stand for 2 h at 41C with 1-2 ng/ml 125 I-VEGF 165 in the presence or absence of a 1000-fold excess of unlabeled VEGF 165 or HARP concentrations ranging from 2 Â 10 À10 to 10 À7 M. The cells were then washed with ice-cold binding buffer and chemically crosslinked for 15 min at room temperature with 0.5 mM DSS. The cell surface was rinsed twice in PBS and the cells were lysed in Laemmli buffer. Covalent 125 I-VEGF 165 -receptor complexes were analysed on 6% SDS polyacrylamide gel. Gels were dried and exposed to a Kodak X-Omat film.
VEGF receptor-based binding assay
Microtiter plates (Costar, ATGC, Orleans, France) with 96 wells were coated with carrier-free human recombinant kinase insert domain containing receptor (KDR)/IgG Fc, Flt-1/IgG Fc, or neuropilin (100 ng/well) in PBS, overnight at 41C. The wells were then washed three times with PBS containing 0.1 % (v/v) Tween 20 (PBS-T) and blocked with 1% BSA in PBS for 2 h at room temperature. The plates were then incubated overnight at 41C with 0.35 pM 125 I-VEGF 165 in the presence of 1 nM unlabeled VEGF 165 or various concentrations of HARP, ranging from 0.02 to 10 nM. After being washed three times with PBS-T, bound proteins were lysed with 0.1 NaOH and counted in a gamma counter (LKB Wallac Minigamma 1275). All the experiments were carried out in duplicate and repeated at least three times.
Expression of HARP wt , HARP 9-59 , HARP 60-110 , HARP 9-110 , and HARP W20A , HARP W74A in Escherichia coli Glutathione S-transferase (GST) fusion proteins were constructed by polymerase chain reaction using the human HARP cDNA as a template. The oligonucleotides were synthesized by incorporating a BamHI restriction site at the 5 0 end and a stopcodon followed by an EcoRI restriction site at the 3 0 end. After digestion by EcoRI and BamHI, the PCR products were further purified and subcloned into the pGEX 2T vector (Amersham Pharmacia Biotech, Orsay, France). HARP W20A and HARP W74A mutants were generated with the Quick-Change site-directed mutagenesis kit (Stratagene Europe, Amsterdam, The Netherlands), using mutant oligonucleotide primers in which the W codons (TGG) at position 20 or 74 were replaced by A codons (GCG). The GST-HARP fusion proteins were isolated by glutathione-agarose affinity, and the GST tag was cleaved by thrombin treatment. Purification of the resulting proteins was achieved by Mono-S chromatography, and the purity and integrity of the proteins were routinely checked by SDS-PAGE (data not shown).
Binding of 125 I-VEGF on HARP-coated wells
Microtiter plates with 96 wells (Costar, ATGC, Orleans, France) were coated overnight at 41C with 200 ng of HARP or mutated HARP proteins diluted in 100 ml of PBS. The plates were then washed twice with PBS-T, blocked with 1% BSA in PBS for 2 h at room temperature, and washed again three times. The HARP-coated wells were incubated for 2 h at room temperature with 125 I-VEGF 165 (200 000 c.p.m./well; 10 ng/ml) with or without various concentrations of competitors, including unlabeled VEGF 165 , heparin, HARP, and HARP peptides, diluted in PBS containing 1% BSA. After this incubation step, unbound 125 I-VEGF 165 was removed by five washes with PBS-T, and bound 125 I-VEGF 165 was solubilized using 200 ml of 0.2 M NaOH and counted with a gamma counter. All experiments were carried out in triplicate and were repeated three times.
Results
HARP inhibited HUVEC proliferation induced by VEGF 165
As shown in Figure 1 , HARP efficiently inhibited VEGF 165 -induced HUVEC proliferation. As compared to the control, HARP in a concentration of 30 nM completely inhibited VEGF 165 -induced HUVEC growth. Note that at this concentration, the basal proliferation of untreated cells was also significantly inhibited. It is noteworthy that no cellular toxicity was observed in the presence of 30 nM HARP. However, about 50% inhibition of specific VEGF 165 -induced HUVEC proliferation occurred in the presence of 3 nM (50 ng/ml) HARP, whereas at this level no effect on the basal proliferation rate was seen. (Figure 2b ), whereas in this concentration no significant effect was observed at the control culture not stimulated by VEGF 165 .
HARP inhibited, in vivo, the Matrigelt infiltration of endothelial cells induced by VEGF 165
The inhibitory effect of HARP on VEGF 165 -induced angiogenesis in vivo was investigated in the Matrigelt plug assay. As compared to control, a five-fold increase in the infiltration of endothelial cells was observed when 1 nM VEGF 165 was added to Matrigelt (Figure 3a We therefore sought to identify the mechanism through which HARP inhibited VEGF 165 binding and activities.
I-VEGF 165 bound to HARP and this interaction was reversed by heparin
All our attempts to show binding of HARP to VEGF receptors were unsuccessful. Consequently, we investigated whether the inhibition of VEGF 165 binding to its cell-surface receptors were caused by a direct interaction (1) The crosslinked complexes were analysed by 7.5% SDS-PAGE followed by autoradiography We used a solid-phase ligand-binding assay to determine which HARP domain was involved in the interaction between HARP and VEGF 165 . To determine whether the lysine-rich domains at the N-and C-terminal parts of the HARP molecule were required for the HARP-VEGF interaction, we examined the ability of HARP 9-110 to bind to 125 I-VEGF 165 . As shown in Figure 7a , the binding of 125 I-VEGF 165 to coated HARP was inhibited in a dose-dependent manner by HARP 9-110 , suggesting that the N-and C-terminal parts of HARP may not be required and that the b-sheet domains of HARP that contain the thrombospondin-like domains may be involved in the HARP-VEGF 165 interaction. To confirm this assumption, we tested the ability of HARP 9-59 and HARP , each containing b-sheet domains of HARP, to inhibit the binding of 125 I-VEGF 165 -coated HARP. As shown in Figure 7a , the two molecules failed to inhibit this binding. To further determine the involvement of the TSR-1 homologue motif present in each b-sheet domains of HARP, two different mutants were constructed (HARP W20A and HARP W74A ) and tested for their ability to bind VEGF 165 . All proteins including mutant HARP proteins and wt HARP as control (200 ng/well) were coated and incubated with increasing concentrations of 125 I-VEGF 165 . As shown in Figure 7b , the 125 I-VEGF 165 bound HARP in a dosedependent and saturable manner. In contrast, mutant proteins failed to bind 125 I-VEGF 165 , suggesting that both TSR-1 motifs of HARP were involved in its binding to VEGF.
Discussion
In the present study, we demonstrated that HARP may negatively regulate angiogenesis by inhibiting VEGF 165 -induced proliferation, migration, and differentiation of HUVEC. In contrast, inhibition of the above processes was minimal when HARP was used alone. For instance, HARP at a concentration of 3 nM caused a 50% inhibition of VEGF 165 -induced proliferation and almost completely abolished VEGF 165 -induced migration and differentiation without affecting the behavior of unstimulated HUVEC cultured without VEGF 165 . These results contrast with those obtained previously with microvascular endothelial cells (Papadimitriou et al., 2001) or on HUVEC stimulated with partially purified supernatants of cells overexpressing HARP (Souttou et al., 2001) . In agreement with our results, we have not detected in HUVEC mRNA expression of anaplastic lymphoma kinase, a receptor that transduces HARPmediated signals. So far, there is no explanation for this discrepancy, but it might be due to differences in culture conditions or the different origins of HUVEC. Our results clearly show that HARP inhibited the VEGF 165 -induced proliferation, migration, and differentiation of HUVEC. Interestingly, we showed that HARP inhibited VEGF 165 -induced angiogenesis by forming a complex. This inhibition was shown by the in vitro assay and further confirmed by the in vivo angiogenesis assay. The mechanism in which the angiostatic effect of HARP on VEGF 165 is attributed to the complex formation between HARP and VEGF 165 is strengthened by the data in which HARP inhibited the binding of VEGF 165 to its high-affinity receptor. We also showed that HARP inhibited the binding of VEGF 165 to immobilized soluble KDR without any effect on the binding of VEGF 165 to immobilized soluble Flt-1. Since these chimeric forms of soluble VEGF receptor bind to VEGF 165 as strongly as do wild-type KDR or Flt-1 (Keyt et al., 1996; Robinson and Stringer, 2001 ), these data suggest that similar structural domains of VEGF 165 are involved in the binding of VEGF with KDR or HARP, but are different from those involved with Flt-1. This possibility is supported by the fact that KDR and Flt-1 receptors bind to different structural sites on VEGF 165 . The identification of VEGF 165 binding determinants on HARP is currently under investigation.
Our observation that HARP bound VEGF 165 prompted us to investigate which molecular domain or domains of HARP were involved in the inhibition of VEGF 165 -induced cell proliferation and differentiation. Recently, a heteronuclear NMR study showed that HARP comprises two b-sheet domains connected by a flexible linker and responsible for heparin binding. In addition, the N-and C-terminal parts of the HARP molecule displayed a lysine-rich sequence that apparently formed random coils. However, although these regions were positively charged, they did not seem to be located in the heparin-binding site of HARP . Sequence comparisons have established that the b-sheet HARP domains display homologies with the thrombospondin type-1 repeat (TSR-1) , and is found in a variety of proteins involved in cellular interactions. In addition, several studies (Guo et al., 1992a, b) have shown that the WXXW sequence of the TSR-1 motif binds to heparin and heparan sulfate and have investigated the mechanisms by which TSP-1 inhibits endothelial cell proliferation and suppresses angiogenesis. The region involved in the inhibition of angiogenesis has been mapped to the procollagen domain and to TSR-1 (Tolsma et al., 1993) . More recently, structure-function analysis has indicated that the ability to repress angiogenesis also involves the second and third type-1 repeats containing the tryptophan/cysteine domain and the CD36 binding region, which act independently to inhibit angiogenesis. Additional studies have demonstrated that mutation of the three tryptophan residues to alanine completely abolished the inhibitory activity, suggesting that these residues may play an important role in the angiostatic properties of TSR-1 domain (Iruela-Arispe et al., 1999) . Note that the amino-acid sequences of the TSR-1-like domain found in HARP are not identical with those in the TSR-1 domain of TSP-1, but contain the motif WXXWXXC characterizing the TSR domain . Moreover, peptides from this region suppress vascular growth induced by proangiogenic factors including VEGF 165 (Iruela-Arispe et al., 1999) . Analysis using the Align sofware (Myers and Miller, 1988) has shown that the sequence homology between HARP and TSP-1 is greatest for the second TSR-1 pattern (not shown), suggesting involvement of this domain in the HARP-VEGF 165 interactions. Since HARP with mutated TSR-1 motif failed to interact with VEGF 165 , it is rational to think that the interaction between HARP and VEGF 165 occurred through the TSR-1 domain of HARP. Similar results have been reported concerning the angiogenic growth factor named connective tissue growth factor (CTGF) (Inoki et al., 2002) . CTGF is a heparin-binding, 38-kDa growth factor and a member of an emerging family of cysteinrich protein. This protein, initially identified in the conditioned media of HUVEC (Bradham et al., 1991) , is characterized by a modular structure with four distinct domains including insulin-like growth factor binding protein, von Willebrand factor type C, TSR-1 repeat, and COOH-terminal domains (Bork, 1993) . Several studies indicated that CTGF is mitogenic and a chemotactic factor for cultured fibroblasts that has been implicated in wound healing (Igarashi et al., 1993) , fibrotic disorders (Igarashi et al., 1996) , and uterine function (Brigstock et al., 1997) . Further studies described that CTGF displayed mitogenic activities for endothelial cells (Shimo et al., 1998) and promoted angiogenesis (Shimo et al., 1999) . More recently, by screening a human chondrocyte cDNA library, it has been demonstrated that CTNF inhibits VEGF 165 -induced in vitro and in vivo angiogenesis through binding to VEGF 165 with a mechanism similar to that described for HARP involving TSR-1 domains (Inoki et al., 2002) . Taken together, these results suggested that the angiogenic activity of VEGF 165 could be inhibited by a family of structural related protein containing in their structure TSR-1 domain. This hypothesis remains to be confirmed by further studies.
Interestingly, the EC 50 of HARP that inhibited VEGF 165 effects was about 2 nM, as compared to 10-100 nM for angiostatin or endostatin. The results reported in this study suggest that the angiogenic molecule HARP can also have angiostatic effects, depending on the microenvironment and the types of cells involved and the presence or not of its high-affinity receptor anaplastic lymphoma kinase on these cells. This invites questions about how the properties of HARP are regulated. Several naturally produced angiostatic molecules including angiostatin (O'Reilly et al., 1994) , endostatin (O'Reilly et al., 1997) , the 16-kDa NH 2 fragment of prolactin (Clapp et al., 1993) , the internal fragment of TSP-1 (Good et al., 1990) , and an NH 2 -terminally truncated fragment of platelet factor 4 (Gupta et al., 1995) are released by proteolytic cleavage of larger molecules, which may be angiogenic. Given our observation that plasmin treatment of HARP generated a proteolytic fragment capable of inhibiting the migration and differentiation of HUVEC (unpublished data), it is tempting to speculate that a similar mechanism may occur for HARP. We are currently investigating this point.
Abbreviations HARP, heparin affin regulatory peptide; VEGF 165 , 165-amino-acid form of vascular endothelial growth factor; HUVECs, human umbilical vein endothelial cells; TSR, thrombospondin repeat; PBS, phosphate buffer saline; DSS, disuccinimidyl suberate; TSP-1, thrombospondin 1; flt-1, fms-like tyrosine kinase-1; KDR, kinase insert domain containing receptor, NP-1 neuropilin-1; GST, glutathione S-transferase.
